OGN · Organon & Co
United States · RS rating 82 · As of 2026-11-03
| Price | 13.85 USD |
|---|---|
| 1-day change | +0.2% |
| RS rating (overall / 1M / 3M / 12M) | 82 / 61 / 71 / 94 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 40 / 50 / 30 |
| Industry group (rank) | Medical-Generic Drugs (136) |
| EPS growth Q/Q | -229.5% |
| Sales growth Q/Q | -5.9% |
| Distance from 52-week high | +0.0% |
| Market cap (USD) | $2.2B |